Navigation Links
Zosano Pharma, Inc. Announces Key Strategic Hire
Date:4/9/2013

FREMONT, Calif., April 9, 2013 /PRNewswire/-- Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today that Chris Krueger has been appointed as the company's Chief Business Officer. In this position, Mr. Krueger will be responsible for the company's business development, legal, and investor relations activities.

"We are delighted to have Chris join our team. He brings extremely valuable and relevant healthcare industry experience to Zosano Pharma. His business development expertise and a track record of building successful businesses will be invaluable as we prepare to advance several of our drug candidates," commented Vikram Lamba, Zosano Chief Executive Officer.

Prior to joining Zosano Pharma, Mr. Krueger served as Senior Vice President and Chief Business Officer at Ardea Biosciences. In addition to several successful financings at Ardea, he completed a $407 million global partnership with Bayer HealthCare. Previously, Mr. Krueger served in senior executive roles at Protemix, Xencor, X-Ceptor Therapeutics and Aurora Biosciences. In his previous roles, he completed a broad range of transactions, including licensing, strategic alliances, mergers and acquisitions and equity and debt financings.  Earlier in his career, Mr. Krueger was a corporate lawyer at Cooley LLP.

"It's exciting for me to join the Zosano team as the company enters its next stage of corporate growth," said Mr. Krueger. "With its novel transdermal drug delivery system, Zosano is poised to develop therapeutic products through its own efforts and through strategic collaborations."

About Zosano Pharma

Zosano Pharma, Inc. is a private biopharmaceutical company and a pioneer in the field of drug delivery systems. Zosano is developing products using ZP Patch Technology, a novel transdermal delivery technology based on microprojections that provide rapid and efficient systemic delivery in a convenient, needle-free, and pain-free system. Zosano is a fully integrated development company with its own cGMP manufacturing facility. The company is developing products with significant commercial potential both independently and in collaboration with strategic partners. Learn more at http://www.zosanopharma.com.


'/>"/>
SOURCE Zosano Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
2. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
3. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
4. InnoPharma, Inc., Announces U.S. FDA Approval of Acetylcysteine Solution, USP, 20% for Inhalation or Oral Administration
5. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
6. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
7. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
8. DFH Pharma, USA Partners with Hetero Group, INDIA to Develop 2nd Generation HIV Maturation Inhibitor Drugs
9. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
10. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
11. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... and Strategies - 2016" report to their offering. ... The latest research Autism ... pricing data and benchmarks in the global Autism Spectrum Disorder market. ... What are the key drugs marketed for Autism Spectrum Disorder ...
(Date:2/23/2017)... -- ITL Limited, ( ASX: ITD ), an innovative diversified healthcare ... ended 31 December 2016 compared with the previous corresponding period. A ... here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: 1.2 ... $15.7m; up 11%) Profit before tax of $2.12m ...
(Date:2/23/2017)... Research and Markets has announced the addition ... 2016" report to their offering. ... The latest research Oesophageal Cancer Drugs Price ... in the global Oesophageal Cancer market. The research answers ... key drugs marketed for Oesophageal Cancer and their clinical attributes? How ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... ... disabilities, it is so critically important that we all are aware of our ... why Mediaplanet is proud to announce the launch of its newest edition of ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Yisrayl Hawkins, ... focuses on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement ... current generation. He explains that the Bible details the current times so plainly ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to Head ... division on February 12th. Ms. Esparza qualified into this prestigious status after ... held in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts in ...
(Date:2/23/2017)... FL (PRWEB) , ... February 23, 2017 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – will return to the La Gorce Country Club in Miami Beach to ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... in thought leadership , media relations, content marketing, social media management, corporate ... several clients already in the state and in nearby New Hampshire, Massachusetts and ...
Breaking Medicine News(10 mins):